Anti-labyrinthin antibodies and vaccines: adenocarcinoma - Mission Therapeutics

Drug Profile

Anti-labyrinthin antibodies and vaccines: adenocarcinoma - Mission Therapeutics

Alternative Names: Adenocarcinoma therapies and diagnostics - ImmvaRx

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmvaRx
  • Class Antibodies; Antibody diagnostics; Cancer vaccines
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Adenocarcinoma

Most Recent Events

  • 18 May 2010 Discontinued - Phase-I/II for Adenocarcinoma in USA (unspecified route)
  • 18 May 2010 Discontinued - Preclinical for Adenocarcinoma (diagnosis) in USA (unspecified route)
  • 07 Jul 2005 No development reported - Preclinical for Adenocarcinoma (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top